Creatine and TBI: The Research on Traumatic Brain Injury

The Metabolic Crisis Following TBI

Within seconds of traumatic brain injury, mechanical disruption of cell membranes causes uncontrolled ion flux across neuronal membranes. Sodium and calcium flood into cells while potassium leaks out. Membrane-bound ion pumps — particularly the Na+/K+-ATPase — activate at maximal capacity to restore electrochemical gradients, consuming ATP at rates far exceeding normal demand.

Simultaneously, the mechanical force damages mitochondria, impairs electron transport chain function, and reduces ATP synthesis capacity. The result is catastrophic: ATP demand spikes while ATP production collapses. This energy mismatch initiates a cascade of secondary injury mechanisms — excitotoxicity, calcium overload, free radical production, and inflammation — that often causes more neuronal death than the initial mechanical impact.

Vespa et al. (2005) used microdialysis in human TBI patients to demonstrate that cerebral metabolic crisis — defined as reduced glucose availability and elevated lactate-to-pyruvate ratios — occurs in over 70% of severe TBI cases and correlates directly with poor neurological outcomes.

Phosphocreatine as the Brain's Energy Buffer

The brain contains approximately 5 mmol/kg of phosphocreatine — lower than skeletal muscle but critically important for neuronal function. The creatine kinase shuttle transfers high-energy phosphate groups from mitochondria to sites of ATP consumption throughout the neuron, including synaptic terminals, ion channels, and axonal transport machinery.

During the acute post-TBI energy crisis, phosphocreatine stores represent the first line of defense against ATP depletion. Higher pre-injury phosphocreatine concentrations extend the window during which neurons can maintain ATP levels despite compromised mitochondrial function. This buffer period may determine which neurons survive the secondary injury cascade and which undergo irreversible damage.

The phosphocreatine system regenerates ATP approximately 12 times faster than oxidative phosphorylation alone, making it disproportionately important during acute metabolic stress when mitochondrial function is impaired.

The Sullivan Landmark Study (2000)

Sullivan et al. (2000) conducted the foundational study in creatine-TBI research. Mice were fed creatine-enriched diets (1% creatine by weight) for varying durations — 1, 3, and 5 days — before receiving controlled cortical impact injury, a standardized model of moderate-to-severe TBI.

Results showed dose-dependent and time-dependent neuroprotection. Animals pre-loaded with creatine for 3 days showed 36% reduction in cortical tissue damage compared to non-supplemented controls. At 5 days of pre-loading, the reduction reached 50% — an effect size rarely seen in experimental neuroprotection research.

The neuroprotection correlated with brain creatine content at the time of injury, confirming that the mechanism was phosphocreatine-mediated energy buffering rather than a pharmacological effect independent of creatine stores. Brain mitochondria from creatine-loaded animals maintained membrane potential and ATP synthesis capacity significantly longer after injury.

Mitochondrial Protection Mechanisms

The neuroprotective effect of creatine extends beyond simple ATP buffering. Scheff and Dhillon (2004) demonstrated that creatine pretreatment preserves mitochondrial function following TBI by stabilizing the mitochondrial permeability transition pore (mPTP) in its closed configuration.

When the mPTP opens — triggered by calcium overload and oxidative stress during TBI — mitochondrial contents including cytochrome c leak into the cytoplasm, initiating caspase-dependent apoptotic cascades. By maintaining mPTP closure for longer, creatine provides a critical time buffer during which calcium homeostasis can be partially restored and the apoptotic cascade averted.

Additionally, creatine functions as a direct antioxidant, scavenging reactive oxygen species (superoxide, hydroxyl radicals, peroxynitrite) that accumulate during the post-TBI oxidative burst. Sestili et al. (2006) demonstrated creatine's capacity to reduce oxidative damage to cellular DNA, lipids, and proteins — damage mechanisms that contribute to delayed neuronal death after TBI.

These multiple protective mechanisms — energy buffering, mitochondrial stabilization, and antioxidant activity — operate simultaneously, which may explain the unusually large effect sizes observed in preclinical studies.

Preclinical Replication and Extension

Following Sullivan's initial report, several groups confirmed and extended the findings. Scheff and Dhillon (2004) showed that creatine-pretreated animals had lower levels of lactate and free fatty acids after TBI — both markers of anaerobic metabolism and membrane degradation respectively — indicating preserved aerobic function and reduced membrane damage.

Rabchevsky et al. (2003) applied the creatine-loading approach to spinal cord injury (a related neurotrauma model) and found analogous neuroprotective effects, suggesting the mechanism generalizes across central nervous system trauma rather than being brain-specific.

Prass et al. (2007) demonstrated that creatine pretreatment also protected against ischemic brain injury (stroke model), reducing infarct volume by 40%. This cross-injury-type protection reinforces the energy-buffering hypothesis — any condition that creates acute brain energy crisis should theoretically benefit from enhanced phosphocreatine reserves.

The consistent replication across laboratories, injury models, and species strengthens the preclinical evidence base substantially. However, the standard translational caveat applies: animal model success does not guarantee human clinical efficacy.

Human Clinical Evidence

The most-cited human TBI-creatine study is the open-label trial by Sakellaris et al. (2006) in 39 children and adolescents (ages 1–18) with moderate-to-severe TBI. The creatine group received 0.4 g/kg/day for six months starting within days of injury. Compared to controls, supplemented patients showed significant improvements across multiple outcome domains: cognitive function (Rancho Los Amigos Scale), communication ability, locomotion, sociability, personality/behavior, and self-care independence.

Post-traumatic amnesia duration was also shorter in the creatine group, and improvements in self-care and communication were statistically significant at multiple follow-up timepoints. These results are encouraging but carry significant methodological limitations: open-label design (no blinding), relatively small sample size, single-center study, and pediatric population (may not generalize to adults).

Sakellaris et al. (2008) published a follow-up analysis from the same cohort, reporting that creatine-supplemented patients had shorter ICU stays, reduced duration of mechanical ventilation, and fewer post-traumatic complications including seizures and headaches.

No large-scale, double-blind, placebo-controlled randomized trial in adult TBI patients has been completed as of 2025. This represents the critical evidence gap in the field.

Pre-Loading vs Post-Injury Supplementation

The distinction between pre-loading (before injury) and post-injury supplementation is fundamental. The animal evidence demonstrates clear benefit from pre-loading: phosphocreatine stores must be elevated at the time of injury to buffer the acute energy crisis. Post-injury supplementation cannot retroactively protect against damage that occurs in the first hours.

However, post-injury supplementation may still provide benefit through different mechanisms: supporting energy metabolism during the subacute recovery phase (days to weeks after injury), reducing ongoing oxidative stress, and facilitating neuroplasticity during rehabilitation. The Sakellaris pediatric trial used post-injury supplementation (initiated within days) and still found positive outcomes.

For populations at known risk of TBI — contact sport athletes, military personnel, fall-risk elderly — the pre-loading strategy is most relevant. Routine creatine supplementation maintains elevated brain phosphocreatine levels, providing passive neuroprotection against unpredictable injury events.

Dosing and Timing Considerations

Brain creatine levels respond more slowly to supplementation than muscle creatine levels due to the blood-brain barrier, which limits creatine transporter access. Dechent et al. (1999) used magnetic resonance spectroscopy to demonstrate that oral creatine supplementation (20 g/day for 4 weeks) increased brain creatine content by approximately 8–9% in healthy volunteers.

This suggests that prophylactic brain loading requires sustained supplementation over weeks rather than days — unlike the rapid 5–7 day muscle saturation timeline. Standard daily dosing (3–5 g/day) maintained over months likely produces optimal brain loading for neuroprotective purposes.

For post-injury supplementation, higher doses have been used. The Sakellaris trial used 0.4 g/kg/day — approximately 10–28 g/day depending on body weight — initiated within days of injury and continued for six months. Whether this dose or a lower maintenance dose is optimal for post-TBI recovery remains undetermined.

Military and Contact Sport Implications

TBI is the signature injury of modern military conflict, primarily from blast exposure (improvised explosive devices), and the most common serious injury in contact sports (football, rugby, hockey, boxing, MMA). The U.S. Department of Defense has identified creatine as a compound of interest for blast-injury neuroprotection.

The Consortium for Health and Military Performance (CHAMP) acknowledges the neuroprotective evidence as an area of active research. Several NFL and rugby organizations have incorporated creatine supplementation partly based on the prophylactic neuroprotection hypothesis, though this remains an off-label rationale rather than an evidence-based clinical recommendation.

If the human evidence catches up to the preclinical promise, routine creatine supplementation in high-risk populations could represent one of the simplest, safest, and most cost-effective neuroprotective interventions available.

Current Research Status

Creatine for TBI is not an approved treatment. No clinical guideline recommends it for brain injury prevention or recovery. The ISSN position stand (Kreider et al., 2017) acknowledges the neuroprotective evidence but does not make TBI-specific recommendations, noting the need for adequately powered human trials.

The evidence level can be characterized as: preclinical — strong and well-replicated; clinical — preliminary and limited by study design. The field requires large, multicenter, double-blind RCTs in adult TBI populations to advance from promising preclinical agent to recommended clinical intervention.

For individuals in high-risk populations already supplementing with creatine for performance or other purposes, the neuroprotection data adds meaningfully to the risk-benefit calculation. For individuals not otherwise considering creatine, the TBI evidence alone is not yet sufficient to recommend supplementation specifically for neuroprotection.

References

1. Sullivan PG, Geiger JD, Mattson MP, Scheff SW. Dietary supplement creatine protects against traumatic brain injury. Ann Neurol. 2000;48(5):723-729. PMID: 11079535.
2. Scheff SW, Dhillon HS. Creatine-enhanced diet alters levels of lactate and free fatty acids after experimental brain injury. Neurochem Res. 2004;29(2):469-479. PMID: 15002745.
3. Sakellaris G, Kotsiou M, Tamiolaki M, et al. Prevention of complications related to traumatic brain injury in children and adolescents with creatine administration: an open label randomized pilot study. J Trauma. 2006;61(2):322-329. PMID: 16917665.
4. Sakellaris G, Nasis G, Kotsiou M, et al. Prevention of traumatic headache, dizziness and fatigue with creatine administration. Acta Paediatr. 2008;97(1):31-34. PMID: 18052999.
5. Sestili P, Martinelli C, Bravi G, et al. Creatine supplementation affords cytoprotection in oxidatively injured cultured mammalian cells via direct antioxidant activity. Free Radic Biol Med. 2006;40(5):837-849. PMID: 16520236.
6. Vespa P, Bergsneider M, Hattori N, et al. Metabolic crisis without brain ischemia is common after traumatic brain injury. J Cereb Blood Flow Metab. 2005;25(6):763-774. PMID: 15716852.
7. Dechent P, Pouwels PJ, Wilken B, Hanefeld F, Frahm J. Increase of total creatine in human brain after oral supplementation of creatine-monohydrate. Am J Physiol. 1999;277(3):R698-R704. PMID: 10484486.
8. Prass K, Royl G, Lindauer U, et al. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J Cereb Blood Flow Metab. 2007;27(3):452-459. PMID: 16773142.
9. Rabchevsky AG, Sullivan PG, Fugaccia I, Scheff SW. Creatine diet supplement for spinal cord injury: influences on functional recovery and tissue sparing. J Neurotrauma. 2003;20(7):659-669. PMID: 12908927.
10. Kreider RB, Kalman DS, Antonio J, et al. International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation. J Int Soc Sports Nutr. 2017;14:18. PMID: 28615996.